Please login to the form below

Not currently logged in
Email:
Password:

hypertension

This page shows the latest hypertension news and features for those working in and with pharma, biotech and healthcare.

Entering the era of digital trials

Entering the era of digital trials

The phenomenon is common enough to have a name: white-coat hypertension.

Latest news

More from news
Approximately 13 fully matching, plus 249 partially matching documents found.

Latest Intelligence

  • Tools for the digital world Tools for the digital world

    One study showed that patients with uncontrolled hypertension and diabetes achieved significantly greater reduction in blood pressure (BP) and LDL cholesterol, and were more likely to reach their BP goal, than

  • Proving real-world value Proving real-world value

    Insights reach R&D that ordinarily take years; beta-blockers, for example, found expanded use to control hypertension only after retrospective analysis of four decades of use in heart attack patients.”.

  • Is it time we stopped talking about adherence? Is it time we stopped talking about adherence?

    The EarthWorks has employed this philosophy to develop award-winning patient support programmes in chronic conditions such as asthma and HIV, and rare, complex conditions such as pulmonary arterial hypertension.

  • Tackling the challenge of non-adherence Tackling the challenge of non-adherence

    80% in just five disease areas - asthma, type 2 diabetes, coronary heart disease, hypertension and schizophrenia - would generate cost-savings in excess of £500m a year. ... were able to identify those with uncontrolled hypertension due to medication non

  • Mobile health and patient outcomes Mobile health and patient outcomes

    diabetes patients to remember their nutritional plan when in a supermarket or advising patients with pulmonary arterial hypertension that their average six-minute walking distance has decreased, prompting them to speak

More from intelligence
Approximately 0 fully matching, plus 33 partially matching documents found.

Latest appointments

  • J&J's Jane Griffiths named global head of Actelion J&J's Jane Griffiths named global head of Actelion

    At that point it will gain marketed products that include a trio of pulmonary artery hypertension (PAH) drugs - Tracleer (bosentan), Opsumit (macitentan) and Uptravi (selexipag).

  • New associate director at Packer Forbes New associate director at Packer Forbes

    Prior to this role she was a brand lead at pharma company Actelion where she spent several years on the marketing of hypertension treatment Tracleer (bosentan), during which time she worked

  • Three directors join UK’s MHRA Three directors join UK’s MHRA

    His research has focused on internal medicine, hypertension and cardiovascular risk management, and he established Edinburgh University's Wellcome Trust cardiovascular research initiative and centre for cardiovascular science.

  • Kite Pharma appoints Zelboraf scientist as CMO Kite Pharma appoints Zelboraf scientist as CMO

    Prior to joining Plexxikon, Dr Nolop was VP of clinical research at CoTherix, where he led the development and US approval for Ventavis (iloprost) to treat pulmonary arterial hypertension (PAH).

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Barber shops provide a short cut to BP reduction

    This is exemplified by black men in the United States, who have higher levels of hypertension than white men, but less contact with doctors. ... They therefore have lower rates of treatment, and more than 3 times the risk of dying due to hypertension.

  • 6 Ways to Make MROC’s Rock

    stand on your head, say cheese and record a video of yourself decanting your pills into a box may not yield the best understanding of how hypertension medication is managed at

  • 6 things that doctors want

    adherence conditions like hypertension– perhaps by prompting patients to follow the prescription or lifestyle advice.What’s key is that technology must make the treatment meaningful to patients. In pain medication

  • Packer Forbes News January 2016

    year. Amy is looking forward to working on a range of therapy areas including pulmonary arterial hypertension and HIV. .

  • Packer Forbes News May 2015

    To date, her therapeutic experience covers sexual health, mental health, endocrinology, oncology, hypertension and diagnostic medicine.

More from PMHub
Approximately 1 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics